Overview

A Phase I, Multicenter, Open-Label, Multi-Part, Dose-escalation Study of RAD1901 in Postmenopausal Women With Advanced Estrogen Receptor Positive and HER2-Negative Breast Cancer

Status:
Completed

Trial end date:
2020-04-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety, tolerability and preliminary efficacy of elacestrant (RAD1901) in patients with advanced ER+, HER2-negative breast cancer.

Phase:

Phase 1

Details

Lead Sponsor:

Radius Health, Inc.
Radius Pharmaceuticals, Inc.

Treatments:

Estrogens